Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

Inclusion Criteria:Patients eligible for inclusion in this study have to fulfill all of the
following criteria:

- Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months
with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and
≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)

- Rheumatoid factor and anti-CCP antibodies negative at screening

- Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or
documented history of plaque psoriasis

- Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization
with inadequate control of symptoms or at least one dose if stopped due to intolerance
to NSAIDs

- Subjects taking corticosteroids must be on a stable dose of ≤10 mg/day prednisone or
equivalent for at least 2 weeks before randomization and should remain on a stable
dose up to Week 24

- Subjects taking MTX (≤ 25 mg/week) are allowed to continue their medication if the
dose is stable for at least 4 weeks before randomization and should remain on a stable
dose up to Week 52.

Exclusion Criteria:Patients fulfilling any of the following criteria are not eligible for
inclusion in this study:

- Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process,
obtained within 3 months prior to screening and evaluated by a qualified physician

- Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone,
morphine)

- Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or
IL-17 receptor

- Ongoing use of prohibited psoriasis treatments / medications (e.g., topical
corticosteroids, UV therapy) at randomization. The following wash out periods need to
be observed:

- Oral or topical retinoids 4 weeks

- Photochemotherapy (e.g. PUVA) 4 weeks

- Phototherapy (UVA or UVB) 2 weeks

- Topical skin treatments (except in face, scalp and genital area during screening, only
corticosteroids with mild to moderate potency) 2 weeks

- Subjects who have ever received biologic immunomodulating agents except for those
targeting TNFα, investigational or approved

- Previous treatment with any cell-depleting therapies including but not limited to
anti-CD20, investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3,
anti-CD19)